Biogen Tempers Outlook After Generic Rival Erodes MS Sales

(Bloomberg) -- Biogen Inc. lowered its financial outlook for the year and said it would buy back $5 billion in stock, as its biggest-selling medicine faced new generic competition.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.